Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.Blue DNA illustrationPhoto of a series of test tubes.Scientific microscope with visual representation of DNA helix

Trethera Successfully Completes Phase 1 Dose Escalation Trial Demonstrating Broad Therapeutic Window, Favorable Safety, and Confirmed Target Engagement

October 28, 2025

Trethera announced completion of the Phase 1 dose-escalation trial for TRE-515 in solid tumors. The drug was well tolerated with no dose-limiting toxicities. Results showed strong safety, confirmed target engagement, and durable tumor control, supporting advancement to Phase 2.

Read More

Trethera Receives $1.8 Million NIH Grant to Advance TRE-515 Development for Crohn’s Disease

September 23, 2025

Trethera received a $1.8M NIH grant to accelerate TRE-515 development for Crohn’s disease. The oral dCK inhibitor showed promising results outperforming Stelara in mice. NIH reviewers called the drug “highly innovative” with “exciting potential” and a “favorable safety profile.”

Read More

Trethera Successfully Completes Enrollment of Phase 1 Dose Escalation Trial for Patients with Solid Tumors

September 10, 2025

Trethera has completed enrollment of its Phase 1 dose escalation trial for TRE-515 in solid tumors. Doses increased 36-fold without dose-limiting toxicities, and early clinical benefit was observed. Data will be presented at an upcoming scientific conference.

Read More

Trethera Awarded $2.3 Million NIH Grant to Study TRE-515 Combined with Radiation Therapy in Prostate Cancer Preclinical Models

August 26, 2025

Trethera has been awarded a $2.3M NIH SBIR grant to evaluate TRE‑515 in combination with radiation therapy against mCRPC in preclinical models—building on its recent FDA Fast Track designation and reinforcing its drug candidate’s therapeutic rationale.

Read More

Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus

August 19, 2025

Trethera has been awarded a $3M NIH SBIR grant to advance TRE‑515 for the treatment of systemic lupus erythematosus (lupus). The funding supports toxicology, pharmacology, and efficacy studies in preclinical models, paving the way toward future clinical trials.

Read More